Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
Cambia visualizzazione
| Taglio della confezione | SKU | Disponibilità | Prezzo |
|---|---|---|---|
| 5 mg | Per conoscere la disponibilità, visualizza il carrello | CHF 104.00 CHF 88.40 | |
| 25 mg | Per conoscere la disponibilità, visualizza il carrello | CHF 418.00 CHF 355.30 |
Informazioni su questo articolo
Formula empirica (notazione di Hill):
C30H35NO3
Numero CAS:
Peso molecolare:
457.60
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Assay:
≥95% (HPLC)
Form:
film or powder (or oil)
CHF 88.40
Prezzo di listinoCHF 104.00Risparmia il 15%Promozione valida solo online
Per conoscere la disponibilità, visualizza il carrello
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiNome del prodotto
Ormeloxifene, ≥95% (HPLC)
assay
≥95% (HPLC)
form
film or powder (or oil)
color
colorless to yellow-white
storage temp.
2-8°C
SMILES string
CC([C@@H](C1=CC=CC=C1)[C@@H]2C3=CC=C(OCCN4CCCC4)C=C3)(C)OC5=C2C=CC(OC)=C5
InChI
1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1
InChI key
XZEUAXYWNKYKPL-WDYNHAJCSA-N
Biochem/physiol Actions
Ormeloxifene (Centchroman) is a non-steroidal selective estrogen receptor modulator (SERM) that exhibit anticancer activity. Ormeloxifene suppresses the ovariectomy-induced bone resorption in rats.
non-steroidal selective estrogen receptor modulator (SERM)
1 of 1
Questo articolo | |||
|---|---|---|---|
| assay ≥95% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| form film or powder (or oil) | form powder | form powder | form powder |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| color colorless to yellow-white | color - | color - | color white to beige |
Classe di stoccaggio
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
William R Surin et al.
Journal of basic and clinical physiology and pharmacology, 1-8 (2014-01-29)
Abstract Background: Cancer is one of the leading causes of morbidity and mortality globally. Cancer-associated thrombosis is well established in clinical settings, and thrombin has been found to induce angiogenesis at cancer sites. This establishes a link between cardiovascular diseases
Bilal Bin Hafeez et al.
Molecular cancer therapeutics, 16(10), 2267-2280 (2017-06-16)
Ormeloxifene is a clinically approved selective estrogen receptor modulator, which has also shown excellent anticancer activity, thus it can be an ideal repurposing pharmacophore. Herein, we report therapeutic effects of ormeloxifene on prostate cancer and elucidate a novel molecular mechanism
Geetika Kharkwal et al.
Journal of molecular endocrinology, 48(3), 261-270 (2012-04-12)
Ormeloxifene (Orm), a triphenylethylene compound, has been established as a selective estrogen receptor modulator (SERM) that suppresses the ovariectomy-induced bone resorption in rats. However, the precise mechanism underlying the bone-preserving action of Orm remains unclear. In this study, we evaluated
Numero articolo commerciale globale
| SKU | GTIN |
|---|---|
| SML2237-5MG | 04061835494774 |
| SML2237-25MG | 04061835494767 |



